CDC-RFA-GH21-2173: Capacity Building and Strengthening of Hospital Infection Control to detect, prevent and respond to antimicrobial resistance in India
Closed
This grant is closed. A newer notice from the same program is forecast: Capacity Building for National Immunization Programs in the Eastern Mediterranean Region (CDC-RFA-JG-27-0070). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control - CGH notices from 2021.
Centers for Disease Control - CGH offered grants to the applicants described in the notice. It expected to make one award worth $205 million in total. Applications closed on July 20, 2021.
From the official notice on Grants.gov, last changed May 18, 2021. Checked November 7, 2026.
- Total funding$205 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | May 18, 2021 |
|---|---|
| Deadline | July 20, 2021 |
| Archived by Grants.gov | August 19, 2021 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
The only eligible applicant to apply for this NOFO is All India Institute of Medical Sciences. The applicant must comply with Government of India Health Ministry’s Screening Committee (HMSC) clearance requirements if required and adhere to Government of India rules and regulations for foreign funding.
Is this a realistic fit?
- Most of the program's money (49% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
Antimicrobial resistance (AMR) is a global patient safety and public health concern. Hospital acquired infections (HAI) lead to adverse outcomes and increased cost of treatment. Effective infection prevention and control (IPC) interventions can reduce HAIs. The Government of India has prioritized combating AMR. The All India Institute of Medical Science (AIIMS) at the direction of the Indian Council of Medical Research (ICMR) is directing the only standardized HAI surveillance network in India with 32 nodal centers in 22 states. Through this NOFO, AIIMS will work with CDC and ICMR to implement a step-wise, scalable approach to generate and report accurate HAI and AMR data. In the first year, sites will perform HAI surveillance, improve antimicrobial use and use data to target IPC activities. Short-term outcomes include develop a trained workforce; ensure standardization of surveillance; and strengthen IPC programs. The long-term objective is a sustainable AMR and HAI surveillance network that produces quality data to inform the development and implementation of evidence-based national policies on IPC, antimicrobial stewardship and HAI prevention. The Government of India has prioritized combating AMR. The All India Institute of Medical Science (AIIMS) at the direction of the Indian Council of Medical Research (ICMR) is directing the only standardized HAI surveillance network in India with 32 nodal centers in 22 states. Through this NOFO, AIIMS will work with CDC and ICMR to implement a step-wise, scalable approach to generate and report accurate HAI and AMR data. In the first year, sites will perform HAI surveillance, improve antimicrobial use and use data to target IPC activities. Short-term outcomes include develop a trained workforce; ensure standardization of surveillance; and strengthen IPC programs. The long-term objective is a sustainable AMR and HAI surveillance network that produces quality data to inform the development and implementation of evidence-based national policies on IPC, antimicrobial stewardship and HAI prevention.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before
From fiscal 2021 to 2025, Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security (93.318) awarded $1.3 billion across 306 grant awards, an average of $4.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| African Field Epidemiology Network LTD | 6 | $147 million | |
| The Task Force for Global Health, Inc. | Georgia | 7 | $138 million |
| World Health Organization, Somalia | 14 | $125 million | |
| Association of Public Health Laboratories, Inc. (the) | Maryland | 3 | $61.5 million |
| The Johns Hopkins University | Maryland | 5 | $42.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0070, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-GH21-2173 still open?
No. It closed on July 20, 2021. A newer notice is forecast: CDC-RFA-JG-27-0070, expected deadline February 12, 2027.
Who can apply for Capacity Building and Strengthening of Hospital Infection Control to detect, prevent and respond to antimicrobial resistance in India?
Centers for Disease Control - CGH accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Capacity Building and Strengthening of Hospital Infection Control to detect, prevent and respond to antimicrobial resistance in India?
Closed July 20, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $205 million in total for one award.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before?
The largest recipients over five fiscal years were African Field Epidemiology Network LTD, The Task Force for Global Health, Inc., World Health Organization, Somalia. The program made 306 awards worth $1.3 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)